Celldex Therapeutics, Inc. (CLDX)

NASDAQ: CLDX · IEX Real-Time Price · USD

37.01

-1.98 (-5.08%)

At close: Jul 2, 2024, 4:00 PM

37.17

+0.16 (0.43%)

After-hours: Jul 2, 2024, 5:41 PM EDT

Celldex Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1994
Revenue	6.88	2.36	4.65	7.42	3.57	Upgrade
Revenue Growth (YoY)	192.02%	-49.32%	-37.30%	107.61%	-62.54%	Upgrade
Gross Profit	6.88	2.36	4.65	7.42	3.57	Upgrade
Selling, General & Admin	30.91	27.2	20.49	14.46	15.43	Upgrade
Research & Development	118.01	82.26	53.31	42.53	42.67	Upgrade
Other Operating Expenses	12.5	15	3.5	18	1.8	Upgrade
Operating Expenses	161.43	124.45	77.3	74.99	59.9	Upgrade
Operating Income	-154.54	-122.1	-72.65	-67.57	-56.33	Upgrade
Other Expense / Income	-13.11	-9.77	-1.91	-6.63	-5.45	Upgrade
Pretax Income	-141.43	-112.33	-70.74	-60.95	-50.88	Upgrade
Income Tax	0	0	-0.23	-1.17	0	Upgrade
Net Income	-141.43	-112.33	-70.51	-59.78	-50.88	Upgrade
Shares Outstanding (Basic)	48	47	43	30	15	Upgrade
Shares Outstanding (Diluted)	48	47	43	30	15	Upgrade
Shares Change	3.33%	9.37%	44.64%	104.32%	38.93%	Upgrade
EPS (Basic)	-2.92	-2.40	-1.64	-2.02	-3.51	Upgrade
EPS (Diluted)	-2.92	-2.40	-1.64	-2.02	-3.51	Upgrade
Free Cash Flow	-109.11	-105.49	-62.13	-41.9	-47.13	Upgrade
Free Cash Flow Per Share	-2.25	-2.25	-1.45	-1.41	-3.25	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-2245.27%	-5180.14%	-1561.99%	-910.92%	-1576.41%	Upgrade
Profit Margin	-2054.76%	-4765.59%	-1516.04%	-805.88%	-1423.96%	Upgrade
Free Cash Flow Margin	-1585.20%	-4475.65%	-1335.86%	-564.86%	-1318.95%	Upgrade
EBITDA	-138.42	-109.43	-67.67	-57.02	-46.02	Upgrade
EBITDA Margin	-2011.06%	-4642.72%	-1454.96%	-768.64%	-1287.99%	Upgrade
Depreciation & Amortization	3.01	2.9	3.07	3.93	4.86	Upgrade
EBIT	-141.43	-112.33	-70.74	-60.95	-50.88	Upgrade
EBIT Margin	-2054.76%	-4765.59%	-1520.92%	-821.61%	-1423.96%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).